ID   RORB_RAT                Reviewed;         470 AA.
AC   P45446;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   29-MAY-2024, entry version 177.
DE   RecName: Full=Nuclear receptor ROR-beta;
DE   AltName: Full=Nuclear receptor RZR-beta;
DE   AltName: Full=Nuclear receptor subfamily 1 group F member 2;
DE   AltName: Full=Retinoid-related orphan receptor-beta;
GN   Name=Rorb; Synonyms=Nr1f2, Rzrb;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=7935491; DOI=10.1210/mend.8.6.7935491;
RA   Carlberg C., Hooft van Huijsduijnen R., Staple J.K., Delamarter J.F.,
RA   Becker-Andre M.;
RT   "RZRs, a new family of retinoid-related orphan receptors that function as
RT   both monomers and homodimers.";
RL   Mol. Endocrinol. 8:757-770(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION AS TRANSCRIPTION ACTIVATOR
RP   (ISOFORMS 1 AND 2), TISSUE SPECIFICITY, DNA-BINDING, AND INDUCTION.
RX   PubMed=9729429; DOI=10.1016/s0378-1119(98)00348-5;
RA   Andre E., Gawlas K., Becker-Andre M.;
RT   "A novel isoform of the orphan nuclear receptor RORbeta is specifically
RT   expressed in pineal gland and retina.";
RL   Gene 216:277-283(1998).
RN   [3]
RP   FUNCTION AS TRANSCRIPTION MODULATOR, SUBUNIT, DNA-BINDING, AND DOMAIN.
RX   PubMed=8816759; DOI=10.1073/pnas.93.19.10105;
RA   Greiner E.F., Kirfel J., Greschik H., Doerflinger U., Becker P., Mercep A.,
RA   Schuele R.;
RT   "Functional analysis of retinoid Z receptor beta, a brain-specific nuclear
RT   orphan receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:10105-10110(1996).
RN   [4]
RP   TISSUE SPECIFICITY.
RX   PubMed=9670004; DOI=10.1093/emboj/17.14.3867;
RA   Andre E., Conquet F., Steinmayr M., Stratton S.C., Porciatti V.,
RA   Becker-Andre M.;
RT   "Disruption of retinoid-related orphan receptor beta changes circadian
RT   behavior, causes retinal degeneration and leads to vacillans phenotype in
RT   mice.";
RL   EMBO J. 17:3867-3877(1998).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 212-463 IN COMPLEX WITH STEARIC
RP   ACID AND NCOA1 PEPTIDE, DOMAIN, AND MUTAGENESIS OF ALA-280; TYR-457 AND
RP   GLU-459.
RX   PubMed=11689423; DOI=10.1093/emboj/20.21.5822;
RA   Stehlin C., Wurtz J.-M., Steinmetz A., Greiner E., Schuele R., Moras D.,
RA   Renaud J.-P.;
RT   "X-ray structure of the orphan nuclear receptor RORbeta ligand-binding
RT   domain in the active conformation.";
RL   EMBO J. 20:5822-5831(2001).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 219-462 IN COMPLEX WITH RETINOIC
RP   ACID AND PEPTIDE SRC-1, FUNCTION AS TRANSCRIPTION ACTIVATOR, AND
RP   IDENTIFICATION OF LIGANDS.
RX   PubMed=12958591; DOI=10.1038/nsb979;
RA   Stehlin-Gaon C., Willmann D., Zeyer D., Sanglier S., van Dorsselaer A.,
RA   Renaud J.-P., Moras D., Schule R.;
RT   "All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR
RT   beta.";
RL   Nat. Struct. Biol. 10:820-825(2003).
CC   -!- FUNCTION: Nuclear receptor that binds DNA as a monomer to ROR response
CC       elements (RORE) containing a single core motif half-site 5'-AGGTCA-3'
CC       preceded by a short A-T-rich sequence. Considered to have intrinsic
CC       transcriptional activity, have some natural ligands such as all-trans
CC       retinoic acid (ATRA) and other retinoids which act as inverse agonists
CC       repressing the transcriptional activity. Required for normal postnatal
CC       development of rod and cone photoreceptor cells. Modulates rod
CC       photoreceptors differentiation at least by inducing the transcription
CC       factor NRL-mediated pathway. In cone photoreceptor cells, regulates
CC       transcription of OPN1SW. Involved in the regulation of the period
CC       length and stability of the circadian rhythm. May control
CC       cytoarchitectural patterning of neocortical neurons during development.
CC       May act in a dose-dependent manner to regulate barrel formation upon
CC       innervation of layer IV neurons by thalamocortical axons. May play a
CC       role in the suppression of osteoblastic differentiation through the
CC       inhibition of RUNX2 transcriptional activity.
CC       {ECO:0000269|PubMed:12958591, ECO:0000269|PubMed:8816759}.
CC   -!- FUNCTION: [Isoform 1]: Critical for hindlimb motor control and for the
CC       differentiation of amacrine and horizontal cells in the retina.
CC       Regulates the expression of PTF1A synergistically with FOXN4 (By
CC       similarity). {ECO:0000250|UniProtKB:Q8R1B8}.
CC   -!- SUBUNIT: Monomer. Interacts with CRX. {ECO:0000269|PubMed:11689423,
CC       ECO:0000269|PubMed:12958591, ECO:0000269|PubMed:8816759}.
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleoplasm
CC       {ECO:0000250|UniProtKB:Q92753}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=2;
CC       Name=2; Synonyms=ROR-beta 2;
CC         IsoId=P45446-2; Sequence=Displayed;
CC       Name=1; Synonyms=ROR-beta 1;
CC         IsoId=P45446-1; Sequence=VSP_022577;
CC   -!- TISSUE SPECIFICITY: Isoform 2 expressed with circadian rhythm in eye
CC       and pineal gland. Isoform 1 expressed in retina cortex, thalamus, and
CC       hypothalamus. {ECO:0000269|PubMed:9670004, ECO:0000269|PubMed:9729429}.
CC   -!- INDUCTION: [Isoform 2]: Oscillates diurnally in eye and pineal gland,
CC       with highest levels shortly after midnight.
CC       {ECO:0000269|PubMed:9729429}.
CC   -!- DOMAIN: AF-2 (activation function-2) motif is required for recruiting
CC       coregulators containing the LXXLL motif, such as NCOA1, and control the
CC       transactivational activity (PubMed:11689423, PubMed:8816759).
CC       {ECO:0000269|PubMed:11689423, ECO:0000269|PubMed:8816759}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Shows a 4-fold higher transcriptional
CC       activation of an optimal promoter compared to isoform 1.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR1
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA42095.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L14610; AAA42095.1; ALT_INIT; Genomic_DNA.
DR   PIR; I65219; I65219.
DR   PDB; 1K4W; X-ray; 1.90 A; A=212-463.
DR   PDB; 1N4H; X-ray; 2.10 A; A=212-470.
DR   PDB; 1NQ7; X-ray; 1.50 A; A=219-462.
DR   PDBsum; 1K4W; -.
DR   PDBsum; 1N4H; -.
DR   PDBsum; 1NQ7; -.
DR   AlphaFoldDB; P45446; -.
DR   SMR; P45446; -.
DR   STRING; 10116.ENSRNOP00000018137; -.
DR   BindingDB; P45446; -.
DR   ChEMBL; CHEMBL4105721; -.
DR   PhosphoSitePlus; P45446; -.
DR   PaxDb; 10116-ENSRNOP00000018137; -.
DR   UCSC; RGD:1306778; rat. [P45446-2]
DR   AGR; RGD:1306778; -.
DR   RGD; 1306778; Rorb.
DR   eggNOG; KOG4216; Eukaryota.
DR   InParanoid; P45446; -.
DR   PhylomeDB; P45446; -.
DR   Reactome; R-RNO-383280; Nuclear Receptor transcription pathway.
DR   EvolutionaryTrace; P45446; -.
DR   PRO; PR:P45446; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005654; C:nucleoplasm; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0008502; F:melatonin receptor activity; IDA:RGD.
DR   GO; GO:0004879; F:nuclear receptor activity; IBA:GO_Central.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; ISO:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0035881; P:amacrine cell differentiation; ISS:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IDA:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IEP:RGD.
DR   GO; GO:0042462; P:eye photoreceptor cell development; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0009725; P:response to hormone; IEP:RGD.
DR   GO; GO:0060041; P:retina development in camera-type eye; ISS:UniProtKB.
DR   GO; GO:0046549; P:retinal cone cell development; ISS:UniProtKB.
DR   GO; GO:0046548; P:retinal rod cell development; ISS:UniProtKB.
DR   GO; GO:0060221; P:retinal rod cell differentiation; ISO:RGD.
DR   GO; GO:0007601; P:visual perception; IEA:UniProtKB-KW.
DR   CDD; cd06968; NR_DBD_ROR; 1.
DR   CDD; cd06939; NR_LBD_ROR_like; 1.
DR   Gene3D; 3.30.50.10; Erythroid Transcription Factor GATA-1, subunit A; 1.
DR   Gene3D; 1.10.565.10; Retinoid X Receptor; 1.
DR   IDEAL; IID50142; -.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR044101; NR_DBD_ROR.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR003079; ROR_rcpt.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   PANTHER; PTHR45805; NUCLEAR HORMONE RECEPTOR HR3-RELATED; 1.
DR   PANTHER; PTHR45805:SF6; NUCLEAR RECEPTOR ROR-BETA; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR01293; RORNUCRECPTR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 1.
DR   SUPFAM; SSF48508; Nuclear receptor ligand-binding domain; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative promoter usage; Biological rhythms;
KW   Developmental protein; DNA-binding; Metal-binding; Nucleus; Receptor;
KW   Reference proteome; Sensory transduction; Transcription;
KW   Transcription regulation; Vision; Zinc; Zinc-finger.
FT   CHAIN           1..470
FT                   /note="Nuclear receptor ROR-beta"
FT                   /id="PRO_0000053516"
FT   DOMAIN          222..460
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT   DNA_BIND        18..93
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         21..41
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         57..81
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   REGION          104..127
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           456..461
FT                   /note="AF-2"
FT   VAR_SEQ         1..13
FT                   /note="MCENQLKTKADGT -> MR (in isoform 1)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_022577"
FT   MUTAGEN         280
FT                   /note="A->F,V,S: Inhibits transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:11689423"
FT   MUTAGEN         280
FT                   /note="A->G: No effect on transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:11689423"
FT   MUTAGEN         457
FT                   /note="Y->A: Inhibits transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:11689423"
FT   MUTAGEN         459
FT                   /note="E->A: Inhibits transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:11689423"
FT   HELIX           220..237
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           242..248
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           255..263
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           266..289
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           292..295
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           299..318
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           319..321
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   TURN            324..327
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   STRAND          328..331
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   STRAND          334..337
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           338..344
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           347..361
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           367..378
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           389..410
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           416..422
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           424..444
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           446..451
FT                   /evidence="ECO:0007829|PDB:1NQ7"
FT   HELIX           455..461
FT                   /evidence="ECO:0007829|PDB:1NQ7"
SQ   SEQUENCE   470 AA;  53201 MW;  FC31D327410FF310 CRC64;
     MCENQLKTKA DGTAQIEVIP CKICGDKSSG IHYGVITCEG CKGFFRRSQQ NNASYSCPRQ
     RNCLIDRTNR NRCQHCRLQK CLALGMSRDA VKFGRMSKKQ RDSLYAEVQK HQQRLQEQRQ
     QQSGEAEALA RVYSSSISNG LSNLNTETGG TYANGHVIDL PKSEGYYNID SGQPSPDQSG
     LDMTGIKQIK QEPIYDLTSV HNLFTYSSFN NGQLAPGITM SEIDRIAQNI IKSHLETCQY
     TMEELHQLAW QTHTYEEIKA YQSKSREALW QQCAIQITHA IQYVVEFAKR ITGFMELCQN
     DQILLLKSGC LEVVLVRMCR AFNPLNNTVL FEGKYGGMQM FKALGSDDLV NEAFDFAKNL
     CSLQLTEEEI ALFSSAVLIS PDRAWLLEPR KVQKLQEKIY FALQHVIQKN HLDDETLAKL
     IAKIPTITAV CNLHGEKLQV FKQSHPDIVN TLFPPLYKEL FNPDCAAVCK
//
